{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:35:32Z","timestamp":1790807732030,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,12,28]],"date-time":"2013-12-28T00:00:00Z","timestamp":1388188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s13277-013-1547-8","type":"journal-article","created":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T06:15:40Z","timestamp":1388124940000},"page":"4185-4189","source":"Crossref","is-referenced-by-count":16,"title":["Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG"],"prefix":"10.1007","volume":"35","author":[{"given":"Ioannis","family":"Zachos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Tzortzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lampros","family":"Mitrakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Samarinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Karatzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Gravas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos P.","family":"Vandoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Melekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Papavassiliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,28]]},"reference":[{"key":"1547_CR1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","volume":"59","author":"M Babjuk","year":"2011","unstructured":"Babjuk M, Oosterlinck W. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59:997\u20131008. doi: 10.1016\/j.eururo.2011.03.017 .","journal-title":"Eur Urol"},{"issue":"5","key":"1547_CR2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766\u201373. doi: 10.1016\/j.eururo.2009.12.024 .","journal-title":"Eur Urol"},{"issue":"6","key":"1547_CR3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.urology.2007.02.064","volume":"69","author":"CT Lee","year":"2007","unstructured":"Lee CT. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology. 2007;69(6):1068\u201372.","journal-title":"Urology"},{"issue":"4","key":"1547_CR4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr HW. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166(4):1296\u20139.","journal-title":"J Urol"},{"issue":"9","key":"1547_CR5","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00432-009-0557-9","volume":"135","author":"I Zachos","year":"2009","unstructured":"Zachos I, Konstantinopoulos PA, et al. Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. J Cancer Res Clin Oncol. 2009;135(9):1169\u201375. doi: 10.1007\/s00432-009-0557-9 .","journal-title":"J Cancer Res Clin Oncol"},{"key":"1547_CR6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ. Predicting recurrence and progression in individual patients with stage Ta-T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466\u201377.","journal-title":"Eur Urol"},{"key":"1547_CR7","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernadez Gomes","year":"2009","unstructured":"Fernadez Gomes J, Madero R. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182:2195\u2013203. doi: 10.1016\/j.juro.2009.07.016 .","journal-title":"J Urol"},{"issue":"1","key":"1547_CR8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-5347(17)40575-1","volume":"141","author":"HW Herr","year":"1989","unstructured":"Herr HW. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol. 1989;141(1):22\u20139.","journal-title":"J Urol"},{"issue":"6","key":"1547_CR9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","volume":"13","author":"HW Herr","year":"1995","unstructured":"Herr HW. Intravesical bacillus Calmette-Gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13(6):1404\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1547_CR10","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0022-5347(01)65458-2","volume":"156","author":"R Hurle","year":"1996","unstructured":"Hurle R. Low dose Pasteur bacillus Calmette-Gu\u00e9rin regimen in stage T1, grade 3 bladder cancer therapy. J Urol. 1996;156(5):1602\u20135.","journal-title":"J Urol"},{"issue":"1","key":"1547_CR11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000019664","volume":"34","author":"T Lebret","year":"1998","unstructured":"Lebret T. Low-dose BCG, instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol. 1998;34(1):67\u201372.","journal-title":"Eur Urol"},{"issue":"8","key":"1547_CR12","doi-asserted-by":"crossref","first-page":"E331","DOI":"10.1111\/bju.12026","volume":"111","author":"B Ali-El-Dein","year":"2013","unstructured":"Ali-El-Dein B, Sooriakumaran P. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre. BJU Int. 2013;111(8):E331\u201341. doi: 10.1111\/bju.12026 .","journal-title":"BJU Int"},{"issue":"7","key":"1547_CR13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","volume":"89","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"2002","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, CUETO (Club Urol\u00f3gico Espa\u00f1ol de Tratamiento Oncol\u00f3gico). Long-term follow-up of a randomized prospective trial comparing a standard 81\u00a0mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27\u00a0mg in superficial bladder cancer. BJU Int. 2002;89(7):671\u201380.","journal-title":"BJU Int"},{"key":"1547_CR14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0090-4295(98)00374-4","volume":"52","author":"G Smits","year":"1998","unstructured":"Smits G. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology. 1998;52:1009\u201314.","journal-title":"Urology"},{"issue":"1","key":"1547_CR15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00005392-200101000-00011","volume":"165","author":"S Bernardini","year":"2001","unstructured":"Bernardini S. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol. 2001;165(1):42\u20136.","journal-title":"J Urol"},{"issue":"2","key":"1547_CR16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","volume":"75","author":"H Akaza","year":"1995","unstructured":"Akaza H. Bacillus Calmette-Gu\u00e9rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer. 1995;75(2):552\u20139.","journal-title":"Cancer"},{"issue":"2 Pt 1","key":"1547_CR17","first-page":"494","volume":"167","author":"JW Davis","year":"2002","unstructured":"Davis JW. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol. 2002;167(2 Pt 1):494\u2013500.","journal-title":"J Urol"},{"issue":"2","key":"1547_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","volume":"48","author":"A Orsola","year":"2005","unstructured":"Orsola A. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005;48(2):231\u20138.","journal-title":"Eur Urol"},{"key":"1547_CR19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)67973-6","volume":"163","author":"T Lebret","year":"2000","unstructured":"Lebret T. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Gu\u00e9rin instillations. J Urol. 2000;163:63\u20137.","journal-title":"J Urol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-1547-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-013-1547-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-1547-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T10:51:33Z","timestamp":1565002293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-013-1547-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,28]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1007\/s13277-013-1547-8","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,28]]}}}